Betterlife Pharma Inc. (BETRF) Stock Price & Analysis

Betterlife Pharma Inc. (BETRF) fell 7.50% to USD 0.15 as of July 25, 2026 at 06:12 UTC, according to Nexqual real-time market data.

BETRF last closed at USD 0.16; the session ranged USD 0.15–0.15 on volume of 80,000 shares. Market capitalization is $24.01M, with a 52-week range of USD 0.03–0.2 (OQB). Source: Nexqual, July 25, 2026 at 06:12 UTC.

Key Statistics (as of July 25, 2026 at 06:12 UTC)

Technical Analysis (BETRF)

Nexqual's technical model rates BETRF "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 06:12 UTC.

Analyst Ratings (BETRF)

Wall Street analysts rate BETRF "None", per Nexqual as of July 25, 2026 at 06:12 UTC.

Earnings (BETRF)

Source: Nexqual, July 25, 2026 at 06:12 UTC.

Financials & Fundamentals (BETRF)

Source: Nexqual, July 25, 2026 at 06:12 UTC.

Financial Health Score (BETRF)

Nexqual rates Betterlife Pharma Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:12 UTC.

Ownership (BETRF)

Source: Nexqual, July 25, 2026 at 06:12 UTC.

Leadership (BETRF)

Betterlife Pharma Inc. is led by Ahmad Doroudian (age 65), Founder, CEO & Director, per Nexqual as of July 25, 2026 at 06:12 UTC.

From Betterlife Pharma Inc.'s Latest SEC 10-K Filing (filed 2019-05-03)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Platform Technologies BiPhasix Transdermal Drug Delivery Technology (Topical Platform) We have acquired worldwide rights from Altum Pharmaceuticals Inc. for its patented topical transdermal drug delivery technology platform, or BiPhasix, which we will use for the delivery and commercialization of cannabinoid, CBD and THC-based products.
• Thrudermic Transdermal Nanotechnology (Topical Platform) We have acquired the worldwide rights to Thrudermic's patented Transdermal Nanotechnology for the development and commercialization of transdermal cannabinoids.
• Subject to meeting annual minimum order quantities, we will receive worldwide exclusive rights to this product, made with patented Micelle technology.
• To develop and maintain our proprietary position, we will rely on patent protection, regulatory protection, trade secrets, know‑how, continuing technological innovations and licensing opportunities.

Partnerships

• On August 7, 2018, we entered into a licensing agreement with Formulex Pharma Innovations (formerly Solubest Ltd.) ("Formulex") whereby we acquired worldwide rights for the use, development and commercialization of its patented Solumer™ Oral Drug Delivery Technology ("Solumer™") for the improved bioavailability, delivery and commercialization of CBD, THC and other biocannabis-based products.
• On September 12, 2017, we entered into a licensing agreement with Altum Pharmaceuticals Inc. ("Altum") whereby we were granted worldwide rights to BiPhasix Transdermal Drug Delivery Technology ("BiPhasix Technology") for the delivery and commercialization of cannabinoids, cannabidiol ("CBD"), and tetrahydrocannabinol ("THC") based products.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:12 UTC. This page is informational and not investment advice.